Key result
Pediatric Fontan patients without antithrombotic therapy had significantly lower platelet thrombogenicity than healthy controls (PL18-AUC10 median 356 vs 408), and T-TAS effectively monitored antithrombotic therapy.
Why the study?
Despite thromboembolic events being a major complication after the Fontan procedure, consensus on optimal antithrombotic therapy is lacking, prompting evaluation of the Total Thrombus-formation Analysis System to assess thrombogenicity.
Does antithrombotic therapy with aspirin and/or warfarin reduce thrombogenicity as measured by T-TAS in pediatric Fontan patients?
Observational (n=50)
No
Does antithrombotic therapy with aspirin and/or warfarin reduce thrombogenicity as measured by T-TAS in pediatric Fontan patients?
The Total Thrombus-formation Analysis System (T-TAS) is a potentially useful tool for quantitatively monitoring thrombogenicity and the effects of antithrombotic therapy in pediatric Fontan patients.
Answers are grounded in this paper and cite their sources.
T-TAS may aid thrombogenicity assessment post-Fontan; hypothesis-generating for tailored antithrombotic strategies.
Background: Despite the major clinical complication of thromboembolic events after the Fontan procedure, there is no consensus regarding the optimal antithrombotic therapy. Novel tools to assess thrombogenicity are desirable to establish optimal thromboprophylaxis in this patient population. The Total Thrombus-formation Analysis System (T-TAS) was developed for the quantitative analysis of thrombus formation using microchips with thrombogenic surfaces. This study evaluated the utility of T-TAS in the assessment of thrombogenicity in pediatric Fontan patients. Methods and results: The participants included 20 consecutive Fontan patients who underwent cardiac catheterization and 30 healthy controls. Blood samples collected without and with antithrombotic therapy (aspirin or aspirin and warfarin) were used for T-TAS to compute the area under the curve (AUC) in the atheroma (AR10-AUC30) and platelet (PL18-AUC10) chips. T-TAS values showed that patients in the Fontan group without antithrombotic therapy had lower thrombogenicity than those in the control group (PL18-AUC10, median [interquartile range] 356 [313–394] vs. 408 [392–424]; AR10-AUC30, median [interquartile range] 1270 [1178–1351] vs. 1382 [1338–1421]). Aspirin and warfarin therapies significantly decreased PL18-AUC10and AR10-AUC30, respectively, compared with those of patients without antithrombotic therapy (P<0.001 for each comparison). Subgroup analysis divided by low (<9 mmHg) or high (≥ 9 mmHg) central venous pressure (CVP) showed that CVP affects the reduction in AR10-AUC30with antithrombotic therapy. Conclusions: T-TAS may be a useful tool for monitoring thrombogenicity and antithrombotic therapy in Fontan patients.
No takes yet. Share an insight, caveat, or question.
Matsuo et al. (2022) conducted an observational in Pediatric Fontan patients (n=50). Fontan physiology vs. Healthy controls was evaluated on Platelet thrombogenicity (PL18-AUC10) (p=<0.001). Pediatric Fontan patients without antithrombotic therapy had significantly lower platelet thrombogenicity than healthy controls (PL18-AUC10 median 356 vs 408), and T-TAS effectively monitored antithrombotic therapy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: